Aprea TherapeuticsAPRE
APRE
About: Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Employees: 8
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 26 [Q4 2024] → 26 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
2.67% less ownership
Funds ownership: 38.19% [Q4 2024] → 35.51% (-2.67%) [Q1 2025]
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
45% less capital invested
Capital invested by funds: $6.83M [Q4 2024] → $3.78M (-$3.05M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for APRE.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial
Neutral
GlobeNewsWire
2 months ago
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition
Neutral
GlobeNewsWire
2 months ago
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR inhibitor ATRN-119; plan to complete dose escalation H2 2025 $22.8 million in cash and cash equivalents as of December 31, 2024 DOYLESTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.
Neutral
GlobeNewsWire
3 months ago
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, announced today that it has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center. Under the agreement, Aprea will supply its proprietary WEE1 kinase inhibitor, APR-1051, to support preclinical research aimed at exploring its potential in treating HPV+ and HPV- head and neck squamous cell carcinoma (HNSCC) expressing genomic markers of replication stress.
Neutral
GlobeNewsWire
4 months ago
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio.
Neutral
GlobeNewsWire
6 months ago
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle
Neutral
Zacks Investment Research
7 months ago
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Aprea Therapeutics (APRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Negative
Zacks Investment Research
7 months ago
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
Aprea Therapeutics, Inc. (APRE) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.86 per share a year ago.
Neutral
GlobeNewsWire
7 months ago
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need; active enrollment is ongoing at three sites in the U.S.
Neutral
GlobeNewsWire
8 months ago
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will participate in two presentations at the Maxim Healthcare Virtual Summit, to take place October 15 to 17, 2024.
Charts implemented using Lightweight Charts™